Eric Cheung
Physician Assistant · Los Angeles, CANPI 1013421973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 382 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 382 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- GSK$1K
- Bayer$852
- Gilead$679
- AbbVie$579
- Novo Nordisk$501
- plus $4K from 27 others
Across 6 payments — averaging $33,903 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coherus Oncology, Inc.$203K
What the payments were for
- Food & beverage$9,314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 86 | $1,446 |
| GSK | 54 | $1,233 |
| Bayer | 36 | $852 |
| Gilead(2 entities) | 14 | $679 |
| AbbVie | 22 | $579 |
| Novo Nordisk | 32 | $501 |
| IBSA Pharma Inc. | 13 | $465 |
| Redhill Biopharma Inc. | 10 | $415 |
| AstraZeneca | 9 | $382 |
| Phathom Pharmaceuticals, Inc. | 7 | $376 |
| Lilly USA, LLC | 15 | $343 |
| Kowa Pharmaceuticals America, Inc. | 16 | $307 |
| Aimmune Therapeutics, Inc. | 8 | $217 |
| Ironwood Pharmaceuticals, Inc | 4 | $182 |
| Boehringer Ingelheim | 7 | $148 |
| Merck | 6 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $138 |
| Exact Sciences | 6 | $134 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Dexcom, Inc. | 4 | $111 |
| Ardelyx, Inc. | 4 | $107 |
| Amarin Pharma, Inc. | 4 | $86 |
| Hikma Pharmaceuticals USA | 4 | $63 |
| Bioventus LLC | 2 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Radius Health, Inc. | 1 | $32 |
| Alkermes, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Qiagen, LLC | 1 | $20 |
| Pfizer | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Cranial Technologies, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,314 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 108 | $109,260 |
| VemlidyTenofovir Alafenamide | 64 | $92,578 |
| KerendiaFinerenone | 69 | $72,218 |
| RybelsusSemaglutide | 37 | $68,607 |
| JanuviaSitagliptin Phosphate | 53 | $50,247 |
| VascepaIcosapent Ethyl | 86 | $49,243 |
| FarxigaDapagliflozin Propanediol | 54 | $46,967 |
| EliquisApixaban | 31 | $44,960 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $38,139 |
| CreonLipase/Protease/Amylase | 24 | $35,026 |
| Icosapent Ethyl | 90 | $26,889 |
| LinzessLinaclotide | 43 | $26,835 |
| Diclofenac Sodium | 67 | $24,155 |
| ProliaDenosumab | 14 | $22,595 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $21,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $148 | $149,120164 claims |
| GileadVemlidy | $679 | $92,57864 claims |
| BayerKerendia | $852 | $72,21869 claims |
| Novo NordiskRybelsus | $501 | $68,60737 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix | $1,233 | $62,980137 claims |
| AbbVieCreon, Linzess | $579 | $61,86167 claims |
| AstraZenecaFarxiga, Brilinta, Bevespi Aerosphere | $382 | $58,98484 claims |
| MerckJanuvia | $145 | $50,24753 claims |
| PfizerEliquis | $17 | $44,96031 claims |
| AmgenProlia | $1,446 | $22,59514 claims |
| Lilly USA, LLCMounjaro | $343 | $10,76411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Los Angeles
- Asia SullivanLos Angeles$61K
- Felipe FindleyLos Angeles$51K
- Melissa GriffinLos Angeles$39K
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.